Date:7/28/2008

are "forward-looking statements" under the securities laws. Words such as, but not limited to, "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," and "could," and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Vanda is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in the company's forward-looking statements include, among others: delays in the completion of Vanda's clinical trials; a failure of Vanda's product candidates to be demonstrably safe and effective; Vanda's failure to obtain regulatory approval for its products or to comply with ongoing regulatory requirements; a lack of acceptance of Vanda's product candidates in the marketplace, or a failure to become or remain profitable; Vanda's inability to obtain the capital necessary to fund its research and development activities; Vanda's failure to identify or obtain rights to new product candidates; Vanda's failure to develop or obtain sales, marketing and distribution resources and expertise or to otherwise manage its growth; a loss of any of Vanda's key scientists or management personnel; losses incurred from product liability claims made against Vanda; a loss of rights to develop and commercialize Vanda's products under its license and sublicense agreements and other factors that are described in the "Risk Factors" section (Part II, Item 1A) of Vanda's quarterly report on Form 10-Q for the quarter ended March 31, 2008 (File No. 000-51863). In addition to the risks described above and in Part II, Item 1A of Vanda's quarterly report on Form 10-Q, other unknown or unpredictable factors also could affect Vanda's results. There can be no assurance that the act
'/>"/>

SOURCE Vanda Pharmaceuticals Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine news :

1. Vanda Pharmaceuticals to Present at the FBR Capital Markets 12th Annual Spring Investor Conference
2. Vanda Pharmaceuticals Announces that it No Longer Intends to Offer Convertible Senior Notes
3. Vanda Pharmaceuticals VSF-173 Excessive Sleepiness Phase II Clinical Trial Suggests Wake-Promoting Properties
4. Vanda Pharmaceuticals to Announce Third Quarter 2007 Financial Results on November 8, 2007
5. Vanda Pharmaceuticals to Present New Data on Iloperidone at the 2007 American Society of Human Genetics Annual Meeting
6. Vanda Pharmaceuticals to Present at Natixis Bleichroeders Hidden Gems Conference
7. Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP
8. New Natural Product from Zurich Pharmaceuticals Downs Appetite
9. AUDIO from Medialink and Duramed Pharmaceuticals: Not Your Mothers Menopause
10. Genesis Pharmaceuticals Announces New Board Member and Forms Committees
11. Sound Pharmaceuticals Receives Additional DoD Funding for Its Hearing Regeneration Product